Suvemcitug is a humanized IgG1kappa antibody targeting VEGF with antiangiogenic activity. Suvemcitug selectively binds to and blocks VEGFA from binding to VEGFR1 and 2, thereby inhibiting its activities and preventing tumor angiogenesis and ultimately suppressing tumor growth and metastasis. Suvemcitug can be used for the study of colorectal cancer[1].
Molecular Weight:
(145.782 kDa)
Purity:
96
CAS Number:
[1610010-57-5]
Target:
VEGFR
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted